Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Frank L. Greenway(Pennington Biomedical Research Center), Eduardo Dunayevich(Neurocrine Biosciences (United States)), Raymond A Plodkowski(Scripps Clinic), Ken Fujioka(Scripps Clinic), Maria Guttadauria, J. Erickson(Clinical Solutions), Dennis Dong Hwan Kim(University Health Network), Sunder Mudaliar(University of California, San Diego)
Cited by 1,018
Related Papers
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
|New England Journal of Medicine|2015|2.6k
American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity
|Endocrine Practice|2016|1.8k
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
|The Lancet|2017|843
Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes
|Diabetes Care|2013|494
Physiological adaptations to weight loss and factors favouring weight regain
|International Journal of Obesity|2015|414